ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

ClinicalTrials.gov ID: NCT03809663

Public ClinicalTrials.gov record NCT03809663. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 12:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined With Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis

Study identification

NCT ID
NCT03809663
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Amgen
Industry
Enrollment
251 participants

Conditions and interventions

Interventions

  • Placebo Other
  • Tezepelumab Drug

Other · Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 14, 2019
Primary completion
May 11, 2020
Completion
Dec 21, 2020
Last update posted
Mar 9, 2022

2019 – 2020

United States locations

U.S. sites
16
U.S. states
12
U.S. cities
15
Facility City State ZIP Site status
First OC Dermatology Fountain Valley California 92708
Clinical Science Institute Santa Monica California 90404
Hamilton Research, LLC Alpharetta Georgia 30022
Southern Illinois University School of Medicine Springfield Illinois 62702
Dundee Dermatology West Dundee Illinois 60118
DS Research Clarksville Indiana 47129
Epiphany Dermatology of Kansas, LLC Overland Park Kansas 66215
Skin Sciences Pllc Louisville Kentucky 40217
Scott Health Services LLC Louisville Kentucky 40241
Clarkston Skin Research Clarkston Michigan 48346
J Woodson Dermatology and Associates Henderson Nevada 89052
Mount Sinai Hospital New York New York 10029
DermResearch Center of New York Inc Stony Brook New York 11790
Tennessee Clinical Research Center Nashville Tennessee 37215
Modern Research Associates Dallas Texas 75231
Premier Clinical Research Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03809663, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 9, 2022 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03809663 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →